logo-loader
viewAvalon GloboCare Corp

Avalon GloboCare scores $20M credit facility from Chairman Daniel Lu

“This funding provides us capital to execute a number of our clinical activities and milestones related to our ongoing cellular immunotherapy, regenerative medicine, as well as exosome-based programs,” CEO David Jin said

One hand holding out coins to another
The unsecured credit facility carries 5% interest and all payments are deferred for 36 months

Avalon GloboCare Corp (NASDAQ:AVCO) received an infusion of cash Tuesday, to the tune of a $20 million credit facility from Chairman Daniel Lu. 

The cell therapeutics company announced in a statement Tuesday morning that the move will allow it to ramp up its clinical studies, research and development programs and commercial activities.

The unsecured credit facility carries 5% interest and all payments are deferred for 36 months. It is not convertible into equity.

READ: Avalon GloboCare wins strategic partnership with GE Healthcare

“This funding provides us capital to execute a number of our clinical activities and milestones related to our ongoing cellular immunotherapy, regenerative medicine, as well as exosome-based programs,” CEO David Jin said in a statement. “We are grateful for our chairman’s continued support and his confidence in the commercial outlook for the business.”

The funds come at a time when the Freehold, New Jersey company recently launched a clinical trial of its immunotherapy treatment and helps the company prepare for others, Jin said. 

“Last month, we initiated our first-in-human clinical trial of CAR-T candidate, AVA-001, in China,” said Jin. ”Concurrently, other immune effector cell therapy candidates are actively undergoing pre-clinical development and validation, with anticipation of more first-in-human clinical studies initiated in year 2020 and beyond. In addition, we are in the planning phase to launch commercial products that leverage our advanced, clinical-grade exosome platform.”

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Quick facts: Avalon GloboCare Corp

Price: 1.5 USD

NASDAQ:AVCO
Market: NASDAQ
Market Cap: $113.66 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avalon GloboCare Corp named herein, including the promotion by the Company of Avalon GloboCare Corp in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Avalon GloboCare reaches 'major clinical milestone' by...

Avalon GloboCare Corp (NASDAQ:AVCO) CEO Dr. David Jin tells Proactive the New Jersey-based company has reached a 'major clinical milestone' by beginning the first-in-human Phase I clinical trial of its flagship AVA-001 therapy in China to treat relapsed/refractory B-cell malignancies, including...

on 10/04/2019

2 min read